Roundtable Discussion: Engineering Next-Generation Tregs to Advance Treg Therapeutic Development

• Investigating engineering Treg cells from CD4+ and iPSC precursors to understand the impact on efficacy
• Examining engineering strategies required to achieve durable Treg stability in vivo for long-term efficacy
• Engineering CAR-Tregs and Allogeneic Tregs for potential therapies of autoimmune and transplant disease
• Growth factor and durability support strategies for long term Treg persistence in patients

Speakers:

Payam Zarin

Associate Director

GentiBio

Fabien Depis

Founder & Chief Executive Officer

TregShield Bio